CHRONIC HEART FAILURE (CHF) IN THE CZECH REPUBLIC: COST-OF-ILLNESS ANALYSIS & DISEASE BURDEN BASED ON AHEAD REGISTRY DATA MININGVALUE IN HEALTHIF62017-10-010OAAI
COST-EFFECTIVENESS OF SACUBITRIL/ VALSARTAN IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE CZECH REPUBLIC: ANALYSIS BASED ON PATIENT CHARACTERISTICS FROM RANDOMIZED CLINICAL TRIAL AND LOCAL REGISTRIESVALUE IN HEALTHIF62016-11-011OAAI
ACCESS TO INNOVATIVE MEDICINES IN THE CZECH REPUBLIC: LENGTH OF PRICE AND REIMBURSEMENT (P&R) PROCEDURESVALUE IN HEALTHIF62016-11-011OAAI
Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based studyEUROPEAN JOURNAL OF HEALTH ECONOMICSIF32016-01-0712PREAI
Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitroBIOCHEMICAL PHARMACOLOGYIF5.62015-12-0127PREAI
COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB COMPARED TO USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE CZECH REPUBLICVALUE IN HEALTHIF62015-11-013OAAI
LC-UV/MS methods for the analysis of prochelator-Boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH)JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSISIF3.12015-02-0115OAAI
COST EFFECTIVENESS OF ROMIPLOSTIM FOR THE TREATMENT OF IMMUNE THROMBOCYTOPENIA (ITP) PATIENTS IN THE CZECH REPUBLICVALUE IN HEALTHIF62014-11-011OAAI
COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTIN-RITUXIMAB COMPARED TO CHOP-RITUXIMAB IN THE TREATMENT OF INDOLENT FOLLICULAR NON-HODGKIN LYMHOMA IN THE CZECH REPUBLICVALUE IN HEALTHIF62014-11-010OAAI
THE IMPACT OF ADHERENCE AND DEVELOPMENT OF NEUTRALIZING ANTIBODIES TO INTERFERONS B ON TREATMENT OF MULTIPLE SCLEROSIS IN THE CZECH REPUBLICVALUE IN HEALTHIF62014-11-010OAAI
COST MINIMIZATION ANALYSIS OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) COMPARED TO RECOMBINANT FACTOR VIIA (RFVIIA) FOR HEMOPHILIA PATIENTS WITH INHIBITORSVALUE IN HEALTHIF62014-11-010OAAI
Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine乙酰胆碱酯酶抑制剂和美金刚治疗阿尔茨海默病的结果EXPERT OPINION ON DRUG SAFETYIF3.12014-06-01291PREAI
COST-EFFECTIVENESS ANALYSIS OF LACOSAMIDE COMPARED WITH STANDARD OF ANTIEPILEPTIC CARE BASED ON CLINICAL PRACTICE DATAVALUE IN HEALTHIF62013-11-010OAAI
COST-EFFECTIVENESS ANALYSIS OF ATORVASTATIN COMPARED TO SIMVASTATIN IN THE PREVENTION OF CARDIOVASCULAR DISEASES IN THE CZECH REPUBLICVALUE IN HEALTHIF62013-11-010OAAI
CLINICAL EFFECTIVENESS OF LACOSAMIDE AND ITS IMPACT ON CONCOMITANT ANTIEPILEPTIC DRUGS CONSUMPTION IN THE CZECH REPUBLICVALUE IN HEALTHIF62013-11-010OAAI
Extended spectrum beta-lactamase and fluoroquinolone resistance genes and plasmids among Escherichia coli isolates from zoo animals, Czech RepublicFEMS MICROBIOLOGY ECOLOGYIF3.22013-06-1949PREAI
Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture mediumJOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSISIF3.12013-03-019PREAI
The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008RHEUMATOLOGY INTERNATIONALIF2.92013-01-136PREAI
Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometryANALYTICAL AND BIOANALYTICAL CHEMISTRYIF3.82012-11-227PREAI
COST-EFFECTIVNESS ANALYSIS OF ONCE DAILY VERSUS TWICE DAILY TACROLIMUS IN POST-RENAL TRANSPLANT PATIENTS IN THE CZECH REPUBLICVALUE IN HEALTHIF62012-11-010OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向